Brown Brothers Harriman & Co’s NovoCure NVCR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15	Closed	-$447	–	1419
2024 Q4	$447	Buy	+15	New	+$317	﹤0.01%	1407
2023 Q4	–	Sell	-6	Closed	-$97	–	1236
2023 Q3	$97	Buy	+6	New	+$173	﹤0.01%	1190
2020 Q1	–	Sell	-144	Closed	-$12K	–	1235
2019 Q4	$12K	Hold	144	–	–	﹤0.01%	868
2019 Q3	$11K	Buy	+144	New	+$11.5K	﹤0.01%	879

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Brown Brothers Harriman & Co's NVCR Position: Q1 2025 in Review

Brown Brothers Harriman & Co sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 15 shares — an estimated $447 sold.

Brown Brothers Harriman & Co first reported a position in NVCR in Q3 2019 and held it in 4 quarters. The position peaked at $12K in Q4 2019. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

Brown Brothers Harriman & Co reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
Brown Brothers Harriman & Co sold 15 NovoCure shares in Q1 2025, an estimated $447.
Brown Brothers Harriman & Co first reported a position in NovoCure in Q3 2019 and held it in 4 quarters.
Brown Brothers Harriman & Co's NovoCure position peaked at $12K in Q4 2019.
227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2025, filed 14 May 2025.